Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

A Phase 1b Study of the Selective HDAC Inhibitor Mocetinostat in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03565406
Recruitment Status : Terminated (recruiting or enrolling participants has halted prematurely and will not resume; participants are no longer being examined or treated)
First Posted : June 21, 2018
Last Update Posted : May 21, 2020
Information provided by (Responsible Party):
NYU Langone Health

No Study Results Posted on for this Study
Recruitment Status : Terminated
Actual Primary Completion Date : January 13, 2020
Actual Study Completion Date : January 13, 2020